PortfoliosLab logo
Bellicum Pharmaceuticals, Inc. (BLCM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0794814048

CUSIP

079481404

IPO Date

Dec 18, 2014

Highlights

Market Cap

$778.33K

EPS (TTM)

-$0.67

Target Price

$5.00

Short %

17.08%

Short Ratio

0.17

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


BLCM

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of BLCM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-46.60%1,072.78%0.00%526.27%
202358.33%-20.79%-63.46%6.06%96.86%-46.30%16.22%-22.09%-1.49%-57.24%58.75%-33.04%-79.17%
20229.40%4.29%27.06%-27.78%-9.62%-15.60%6.47%-0.55%-4.76%-11.67%-1.89%-30.77%-51.68%
202131.73%-6.02%-13.96%-1.86%-19.24%10.74%-9.39%1.34%-3.63%-30.48%-14.29%-14.37%-57.79%
2020-5.43%-26.23%-47.67%6.16%52.60%-2.62%-9.69%-11.33%10.42%-43.53%-0.54%-4.34%-72.64%
201913.01%-2.73%4.98%-9.50%-32.46%-17.48%-15.29%-19.44%-9.48%-21.85%5.68%48.75%-55.82%
2018-27.71%14.31%-5.61%1.98%20.78%-8.66%-13.82%13.68%-14.80%-33.93%12.29%-36.11%-65.28%
2017-1.76%-7.85%0.08%8.35%-20.79%10.29%-9.42%2.36%6.65%-18.44%6.48%-16.15%-38.25%
2016-44.25%-20.18%3.66%8.45%15.09%11.05%22.53%8.44%15.56%-16.78%8.27%-24.04%-32.81%
20157.25%-6.03%-0.22%3.50%3.17%-14.03%-4.33%-16.17%-14.83%-13.90%84.09%-11.98%-12.02%
2014-3.52%-3.52%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bellicum Pharmaceuticals, Inc. (BLCM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Bellicum Pharmaceuticals, Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


Bellicum Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bellicum Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bellicum Pharmaceuticals, Inc. was 99.98%, occurring on Feb 23, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.98%Jan 12, 20152295Feb 23, 2024
-19.93%Dec 19, 20143Dec 23, 20147Jan 5, 201510

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bellicum Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Bellicum Pharmaceuticals, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 77.8% positive surprise.


-10.00-8.00-6.00-4.00-2.000.002.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJuly
-0.02
-0.09
Actual
Estimate

Valuation

The Valuation section provides an overview of how Bellicum Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BLCM compared to other companies in the Biotechnology industry. BLCM currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BLCM relative to other companies in the Biotechnology industry. Currently, BLCM has a P/S ratio of 0.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BLCM in comparison with other companies in the Biotechnology industry. Currently, BLCM has a P/B value of 40.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items